Sign In
Buy DARE
$2.07
+0.0200 (+0.98%)
At Close: Jun 23, 2026
Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026
09:20am, Thursday, 18'th Jun 2026
President and CEO, Sabrina Martucci Johnson, to participate in featured industry panels and present Company's vision for transforming women's health President and CEO, Sabrina Martucci Johnson, to par
Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 million Funding award milestone follows Daré's announcement last week of t
Each year, an estimated six million women in the United States acquire a high-risk HPV infection — and there are no FDA-approved treatments DARE-HPV development is backed by a $10 million U.S. gover
Daré Bioscience, Inc. (DARE) Q1 2026 Earnings Call Transcript
09:40pm, Thursday, 14'th May 2026
Daré Bioscience, Inc. (DARE) Q1 2026 Earnings Call Transcript
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update
04:01pm, Thursday, 14'th May 2026
Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summe
Why Is Nano-Cap Dare Bioscience Stock Trading Higher On Tuesday?
02:21pm, Tuesday, 12'th May 2026
Shares of Dare Bioscience, Inc. (NASDAQ:DARE) are trading higher on Tuesday as the company is reporting positive interim results from its Phase 3 clinical trial for Ovaprene, a hormone-free contracept
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
08:00am, Tuesday, 12'th May 2026
Second Positive DSMB Review Supports Continued Study Progress Interim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive SAN DI
Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026
08:00am, Thursday, 07'th May 2026
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising scienc
Daré Bioscience, Inc. (DARE) Q4 2025 Earnings Call Transcript
06:56pm, Thursday, 26'th Mar 2026
Daré Bioscience, Inc. (DARE) Q4 2025 Earnings Call Transcript
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates
06:21pm, Thursday, 26'th Mar 2026
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.64 per share a year ago.
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
04:01pm, Thursday, 26'th Mar 2026
Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts
On National Viagra Day, Women Finally Claim Their Turn:
08:00am, Monday, 23'rd Mar 2026
DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For Her DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For Her
• Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026 • DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options
Daré Bioscience Participates in Virtual Investor “What This Means” Segment
08:00am, Thursday, 12'th Mar 2026
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses FDA clearance of the IND for DARE-HPV, the planned Phase 2 clinical study, and what the program could mean for women's health
DARE-HPV development supported by $10 million ARPA-H contract; program targets major unmet need with no FDA-approved therapies DARE-HPV development supported by $10 million ARPA-H contract; program ta
